Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8


CD20-TCB with Obinutuzumab Pretreatment as Next-Generation Treatment of Hematologic Malignancies.

Bacac M, Colombetti S, Herter S, Sam J, Perro M, Chen S, Bianchi R, Richard M, Schoenle A, Nicolini V, Diggelmann S, Limani F, Schlenker R, Hüsser T, Richter W, Bray-French K, Hinton H, Giusti AM, Freimoser-Grundschober A, Lariviere L, Neumann C, Klein C, Umaña P.

Clin Cancer Res. 2018 May 1. doi: 10.1158/1078-0432.CCR-18-0455. [Epub ahead of print]


Pharmacokinetic properties of radiolabeled mutant Interleukin-2v: a PET imaging study.

Hartimath SV, Manuelli V, Zijlma R, Signore A, Nayak TK, Freimoser-Grundschober A, Klein C, Dierckx RAJO, de Vries EFJ.

Oncotarget. 2018 Jan 2;9(6):7162-7174. doi: 10.18632/oncotarget.23852. eCollection 2018 Jan 23.


Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines.

Klein C, Waldhauer I, Nicolini VG, Freimoser-Grundschober A, Nayak T, Vugts DJ, Dunn C, Bolijn M, Benz J, Stihle M, Lang S, Roemmele M, Hofer T, van Puijenbroek E, Wittig D, Moser S, Ast O, Brünker P, Gorr IH, Neumann S, de Vera Mudry MC, Hinton H, Crameri F, Saro J, Evers S, Gerdes C, Bacac M, van Dongen G, Moessner E, Umaña P.

Oncoimmunology. 2017 Jan 11;6(3):e1277306. doi: 10.1080/2162402X.2016.1277306. eCollection 2017.


In Vivo Fluorescence Imaging of the Activity of CEA TCB, a Novel T-Cell Bispecific Antibody, Reveals Highly Specific Tumor Targeting and Fast Induction of T-Cell-Mediated Tumor Killing.

Lehmann S, Perera R, Grimm HP, Sam J, Colombetti S, Fauti T, Fahrni L, Schaller T, Freimoser-Grundschober A, Zielonka J, Stoma S, Rudin M, Klein C, Umana P, Gerdes C, Bacac M.

Clin Cancer Res. 2016 Sep 1;22(17):4417-27. doi: 10.1158/1078-0432.CCR-15-2622. Epub 2016 Apr 26.


Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin αvβ3.

Terry SY, Koenders MI, Franssen GM, Nayak TK, Freimoser-Grundschober A, Klein C, Oyen WJ, Boerman OC, Laverman P.

J Nucl Med. 2016 Mar;57(3):467-72. doi: 10.2967/jnumed.115.162628. Epub 2015 Dec 3.


Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis.

Laverman P, van der Geest T, Terry SY, Gerrits D, Walgreen B, Helsen MM, Nayak TK, Freimoser-Grundschober A, Waldhauer I, Hosse RJ, Moessner E, Umana P, Klein C, Oyen WJ, Koenders MI, Boerman OC.

J Nucl Med. 2015 May;56(5):778-83. doi: 10.2967/jnumed.114.152959. Epub 2015 Apr 9.


Sustained in vivo signaling by long-lived IL-2 induces prolonged increases of regulatory T cells.

Bell CJ, Sun Y, Nowak UM, Clark J, Howlett S, Pekalski ML, Yang X, Ast O, Waldhauer I, Freimoser-Grundschober A, Moessner E, Umana P, Klein C, Hosse RJ, Wicker LS, Peterson LB.

J Autoimmun. 2015 Jan;56:66-80. doi: 10.1016/j.jaut.2014.10.002. Epub 2014 Oct 30.


Temporal expression profiles of organic anion transport proteins in placenta and fetal liver of the rat.

St-Pierre MV, Stallmach T, Freimoser Grundschober A, Dufour JF, Serrano MA, Marin JJ, Sugiyama Y, Meier PJ.

Am J Physiol Regul Integr Comp Physiol. 2004 Dec;287(6):R1505-16. Epub 2004 Sep 2.

Supplemental Content

Loading ...
Support Center